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Abstract 
Introduction and Objective 
Nephrocalcinosis (NC) is commonly present in primary hyperparathyroidism (HPT), 
distal renal tubular acidosis (dRTA), and medullary sponge kidney disease (MSKD) but 
has not been studied in patients with CaP stones who do not have systemic disease. 
 
Methods 
We studied patients undergoing percutaneous nephrolithotomy (PNL) who had CaP or 
CaOx stones and did not have HPT, dRTA, or MSKD.  On post-op (PO) day 1, all 
patients underwent a non-contrast CT scan.  If there were no residual calcifications, the 
patient was categorized as not having NC.  If there were residual calcifications, the 
patient underwent a secondary PNL.  If the calcifications were found to be stones then the 
patient was categorized as not having NC.  If the calcifications were not stones then the 
patient was categorized as having NC.  Patients were grouped based on the type of stones 
they formed:  hydroxyapatite (HASF), brushite (BRSF), and idiopathic calcium oxalate 
(ICSF).  The extent of NC was quantified:  0=absence of NC and 3=extensive NC.  
Patients with residual calcifications on PO day 1 NCCT scan who did not undergo 
secondary PNL were excluded.  The presence or absence of NC was correlated with 
metabolic studies. 
 
Results 
67 patients were studied (14 HASF, 19 BRSF, and 34 ICSF).  NC was present in 10/14 
(71.4%), 11/19 (57.9%) and 6/34 (17.6%) for the HASF, BRSF, and ICSF groups 
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respectively (Chi-square (X2):  p=0.01) (Table 1).  The extent of NC per group was 1.98, 
1.32, and 0.18 for HASF, BRSF, and ICSF respectively (p=<0.001).  The presence of NC 
was positively correlated with urine calcium excretion (287.39±112.49 v. 223.68±100.67, 
p=0.03). 
 
Conclusions 
Patients without systemic disease who form hydroxyapatite and brushite stones 
commonly have coexistent NC.  NC can occur in calcium oxalate stone formers but the 
quantity and frequency of NC in this group is dramatically less.  
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Introduction 
The term nephrocalcinosis (NC) is commonly used to describe renal parenchymal 
calcifications.  NC was originally defined by Albright in 1934 as diffuse renal 
calcifications in patients with primary hyperparathyroidism (HPT)1.  The pathological 
definition of NC is the presence of calcium crystal deposits within renal tissue.  From this 
perspective, virtually all calcium stone formers have NC either in the form of interstitial 
deposits of HA, so called Randall’s plaque, over which CaOx stones form (ICSF) or as in 
collecting duct (CD) and Bellini duct (BD) plugs of calcium phosphate (CaP) in CaP and 
brushite (BR) stone formers (HASF, BRSF).  These crystals can be calcium oxalate 
(CaOx) or calcium phosphate (CaP).  The more clinically relevant definition is the 
radiographic definition of NC which is the presence of diffuse, fine renal parenchymal 
calcifications detectable radiolographically2.  The most common causes of NC are 
primary HPT, medullary sponge kidney disease (MSKD), and Type 1 or distal renal 
tubular acidosis (dRTA).  The majority of calcifications associated with the above 
mentioned conditions are easily seen on standard radiographs.  HPT, dRTA, and MSKD 
typically cause both NC and nephrolithiasis.  Distinguishing between these two entities 
clinically and radiographically can be a challenge.  Fortunately, improvements in 
endourologic technology and techniques now allow urologists to distinguish between NC 
and nephrolithiasis3-4.  As mentioned above, NC is associated with a number of systemic 
diseases.  However, NC can also be present when systemic disease is not evident.  To our 
knowledge, no study has looked at the incidence/prevalence of NC in patients with CaP 
and CaOx nephrolithiasis who do not have systemic disease. 
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 Although patients with calcium nephrolithiasis in the absence of systemic disease 
have historically been grouped together, our work over the past decade has documented 
that such patients represent a heterogeneous group, especially when viewed in the context 
of the histopathologic findings noted from papillary and cortical biopsies taken during 
percutaneous stone removal (PNL).  We have identified two broad pathways for the 
initiation of calcium nephrolithiasis5.  The first and largest group, idiopathic calcium 
oxalate stone formers (ICSF) entails CaOx overgrowth on interstitial deposits of 
hydroxyapatite named Randall’s plaque for their describer6,7 (Figure 1A).  The second 
group, calcium phosphate stone formers (IPSF) is strongly associated with intratubular 
crystal deposits, a feature noticeably absent from ICSF8-9 (Figure 1B).  IPSF comprise 
two subsets, those which contain some brushite (BRSF) and those that are predominantly 
hydroxyapatite or calcium phosphate (HASF) with brushite being absent.  HASF and 
BRSF, while both containing intratubular deposits, differ sufficiently in their renal 
pathology and crystal deposits to establish themselves as distinct and separate clinical 
phenotypes9-10 (Table 1).  The primary objective of this study was to contrast the 
frequency and extent of nephrocalcinosis in these three groups of calcium stone formers 
who were carefully studied endoscopically to distinguish between stones and tissue 
deposits.  The uniquely different patients with medullary sponge kidney are not addressed 
here11.   
 
Materials and Methods 
Patients who underwent percutaneous nephrolithotomy (PNL) for calcium urolithiasis  
who underwent digital video mapping, as well as biopsy of the renal cortex and papilla as 
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part of our NIH supported stone pathogenesis project, were entered in this study 
(NIDDK#P01DK56788).  The clinical and histopathologic findings in this cohort of 
patients is the subject of another report9.  The study was approved by the Indiana 
University Institutional Review Board (#1010002261).   
 
The IPSF were separated into two groups, HASF and BRSF.  A cut point of 50% HA as 
an average of all analyzed stone material was utilized to distinguish between HASF and 
ICSF.  All calculi were analyzed by micro-CT, a non-destructive technique followed by 
FTIR spectroscopy.  Patients with any struvite were excluded.  In addition to a medical 
history and physical examination, all patients had blood and 24 hour urine studies to 
exclude systemic diseases including dRTA and primary HPT.  On post-operative (PO) 
day 1, all patients underwent a non-contrast CT examining for residual calcifications.  If 
there were no residual calcifications, the patient was categorized as not having NC.  If 
there were residual calcifications, the patient underwent a thorough second look 
nephroscopy to determine if the residual calcifications were NC or nephrolithiasis.  
Patients with subcapsular, perinephric, and nephrostomy tract calcifications were 
excluded.  Some details about the technical aspects of the second look nephroscopy are 
important.  Although we use digital flexible instruments for mapping at the primary PNL 
procedure, these instruments are not used during the second look nephroscopy 
procedures.  Digital instruments have limited maneuverability due to the metal cap at the 
tip of the endoscope which limits the deflectability of the scope.  During second look 
nephroscopy procedures, both Storz and Pentax flexible nephroscopes are utilized.  
Flexible ureteroscopes are also used when there is a difficult to locate calyx or when the 
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infundibulum to a given calyx is not accommodating.  In addition, if a calcification is 
visible on fluoroscopy but not able to be identified endoscopically, a puncture is 
performed down on to the calcification utilizing an 18-gauge needle and a zip or 
glidewire is passed into the more central renal collecting system.  The wire is then pulled 
out through and through and is followed to lead to the occult calyx of interest.  When this 
so called non-dilated puncture technique is utilized, a skin incision is not required, no 
dilation of the access is required, and a nephrostomy tube is not employed afterwards.  If 
on secondary nephrolithotomy the calcifications were found to be stones then the patient 
was categorized as not having NC.  However, if calcifications identified on CT were not 
identified endoscopically then the patient was categorized as having NC.  Patients were 
grouped based on the type of stones that they formed:  HASF, BRSF, and ICSF.  The 
extent of NC was also quantified:  0=absence of NC, 1=minimal NC, 2=moderate NC, 
and 3=extensive NC (Figure 2).  Patients with residual calcifications on their PO day 1 
CT scan who did not undergo a second look nephroscopy were excluded as we were 
unable to determine if the residual calcifications were stones or NC. 
 All CT scans were done at Methodist Hospital and were interpreted by a single 
radiologist (TH) who was blinded to the endoscopic findings. 
All analyses were performed using SPSS Statistical Software, release 19.0 (SPSS 
Inc., Chicago, IL, USA).  In all tests, a two-tailed significance level of 0.05 was used.  
 
Results 
 We had a total of 54 patients (11 HASF, 15 BRSF, and 28 ICSF) and 67 renal 
units (14 HASF, 19 BRSF, and 34 ICSF).  Table 2 displays each patient in our study 
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categorized by stone type, presence or absence of NC, and location and quantity of NC, if 
present.  NC was present in the majority of HASF 10/14 (71.4%) and BRSF 11/19 
(57.9%), and a minority of ICSF 6/34 (17.6%) patients respectively (Chi-square (X2): 
p=0.01).  All patients in the HASF group who had NC had grades 2 or 3.  There were no 
patients in the HASF group who had grade 1 NC.  Similarly, the majority of the BRSF 
who had NC had grade 3, as well.  In contrast, all patients in the ICSF group who had NC 
had grade 1.  No patient in the ICSF group who had NC had a grade 2 or 3.  The mean 
grade of NC was 1.98, 1.32, and 0.18 for the HASF, BRSF, and ICSF groups respectively 
(p<=0.001) (Table 3).  
 Urinary calcium excretion and calcium phosphate supersaturation were 
significantly higher in those patients exhibiting NC (Table 4).  There was no correlation 
with the percent HA or BR and the presence of NC. 
 
Discussion 
 As evidenced by the original definition proposed by Dr. Albright, NC has become 
highly associated with the etiologies of primary HPT, dRTA, and medullary sponge 
kidney.  NC is not thought to be common in stone formers without systemic disease.  
However, no one has ever looked at the incidence/prevalence of NC in a cohort of 
patients with calcium nephrolithiasis who do not have systemic disease.  The main reason 
for this is that in the past we did not have the ability to make the distinction between NC 
and nephrolithiasis.  With the dramatic improvements in endourologic technology, we are 
now able to distinguish between these two entities.  
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The radiologist is usually one of the first to suggest the presence of NC.  
However, studies have shown that the radiologist’s ability to detect NC is often not 
accurate12,13.  The most sensitive radiological tool to detect NC is computed tomography 
and standard x-rays are used to follow the course of NC14.  Although ultrasound is the 
modality of choice for assessing pediatric NC it is rarely used in the adult population 
because it is subjective and lacks specificity13,14.  The diagnosis of NC can be suggested 
on ultrasound, abdominal x-ray and computed tomography however none possesses 
diagnostic capacity to distinguish between NC and stone4.  Additionally, it is our 
experience that even when the radiologist suggests a diagnosis of NC, on numerous 
occasions we have found stones to be present on endoscopic evaluation and treatment15.  
In the past, all calcium stone formers have been considered as a single group.  
However, our previous work has demonstrated that a significant difference exists 
between CaP stone formers and ICSF.  Moreover, there is also a distinct difference 
between HASF and BRSF.  This paper further substantiates the underlying difference 
between these three calcium stone forming groups.  
 Our main finding is that NC is common even in the absence of systemic disease.  
More specifically, in calcium stone forming patients who do not have primary HPT, 
dRTA or MSKD, a significant number of these patients will have NC.  Previously, absent 
these conditions, NC has not been thought to be a common occurrence, however, there 
are no formal studies addressing the issue.  The data presented herein are the first to 
document the incidence/prevalence of NC in patients with calcium urolithiasis who do 
not have systemic disease or MSKD and has been made possible by the dramatic 
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advances in endourologic technology and techniques of the current era of nephrolithiasis 
surgery. 
 Our observation that NC can occur and indeed is common in the absence of 
systemic disease is noteworthy given the increasing incidence of HASF and BRSF16,17.  
Viewed from another perspective, based on these data, the majority of patients with 
predominantly calcium phosphate stone may be expected to have concomitant NC in the 
absence of systemic disease.  The implications of our findings are important emphasizing 
the advantages of endourologic approaches such as PCNL and URS over ESWL which 
cannot discriminate NL from NC. 
 The characteristics of NC in ICSF patients differs significantly from HASF and 
BRSF both in the frequency and amount of NC present as would be expected given our 
understanding of the pathophysiology of ICSF.  While it is possible that the NC found in 
ICSF could be explained by stones which were overlooked during the secondary PCNL, 
we think this is unlikely given the extensive use of multiple flexible instruments and non-
dilated punctures during the procedures.  The amount of NC when present in ICSF was 
dramatically less than observed in the HASF and BRSF. 
 In concordance with our earlier work, the presence of NC is another factor that 
can be used to distinguish the three calcium forming groups:  HASF, BRSF, and ICSF.  
As we have demonstrated here, NC is prevalent in the majority of HASF and BRSF 
patients but rare in the ICSF group.  These findings are entirely consistent with the 
differing pathways for stone formation for CaP and CaOx stones:  intra-tubular deposits 
are greater in the HASF and BRSF groups and non-existent in the ICSF group.  
Additionally, urinary pH, supersaturation of CaP, and calcium excretion were 
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significantly greater in the HASF and BRSF groups compared to the ICSF groups in this 
cohort of patients9.  
 
Conclusion 
 The only accurate method to distinguish between NC and nephrolithiasis is 
endoscopically.  Using endoscopic techniques, we have demonstrated that patients 
without systemic disease who form HA and BR stones commonly have coexistent NC.  
NC can occur in ICSF, as well.  However, the quantity and frequency of NC in this group 
of patients is dramatically less than in patients who form calcium phosphate stones.  
 
Supported in part by an NIH grant PO1DK56788.  
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FIGURE LEGENDS: 
 
Figure 1A:  A papillae from an ICSF patient showing a small amount of Randall’s plaque 
(arrows).  The papillae is otherwise normal appearing.   
Figure 1B:  A papillae from a BRSF patient.  The papillae is severely diseased.  It is 
flattened.  In the center of the papillae is a grossly dilated Bellini duct (asterisk).  In 
addition to Randall’s plaque (arrows), Bellini duct deposits are seen (arrowheads). 
 
 
Figure 2:  Extent of nephrocalcinosis:  A, minimal; B, moderate; C, extensive.  Arrows 
depict nephrostomy tubes. 
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Table 1:  Clinical features of calcium stone phenotypes 
 Idiopathic Calcium 
Oxalate Stone 
Formers  
(ICSF) 
Brushite Stone 
Formers  
(BRSF) 
Hydroxyapatite 
Stone Formers 
(HASF) 
RP abundance +++ +++ + 
Stone hardness ++ ++++ + 
pH NL ↑ ↑ 
M/F ratio 3/2 3/2 1/5 
Stone on RP ++++ + + 
Papillary injury Rare Severe Moderate 
BR in stones No Yes No 
 
1  
Table 2 
 Right Quantity Location Left Quantity Location 
Hydroxyapatite 1  No   2 Excluded; no secondary 3 Yes Moderate CM;diffuse Yes Moderate CM;diffuse 4 No    5  Yes Moderate CM;diffuse 6  Yes Min-Mod Punctate Papillary; diffuse 7 Yes Min-Mod Punctate CM;mid-upper pole Yes Min-Mod Punctate CM:mid-upper pole 8 Yes Moderate Punctate CM;diffuse Yes Moderate Punctate CM;diffuse 9  No   10  No   11 Yes Moderate CM;diffuse Yes Moderate CM;diffuse 
Brushite 1 Excluded; no secondary 2  Yes Single; Punctate Cortical; midpole 3 Yes Single; Punctate CM;upper pole No   4 Yes Moderate CM;diffuse Yes Moderate CM;diffuse 5  Yes 3; punctate CM; midpole 6  No   7 Yes Moderate CM/papillary; diffuse  8 No      9    No   10 Yes Moderate CM/diffuse Yes Moderate CM/diffuse 11 Yes Moderate CM/papillary; diffuse Yes Moderate CM/papillary; diffuse 12  No   13 No   No   14 Yes Minimal Punctate CM;upper and mid pole No   15 Excluded; no secondary 
Calcium oxalate 1 Excluded; no secondary 2  No   3 No    4 No   Yes Single; papillary 
2  
punctate 5 Yes Single; punctate papillary No   6 No   No   7 Excluded; no secondary 8 Excluded; no secondary 9 No   No   10  No   11 No    12 Yes Single; punctate papillary No   13 No    14 Excluded; no secondary 15  No   16  No   17  No   18 No   No   19 No    20  Yes 5; punctate CM;diffuse 21 No    22  No   23 No    24 No   Yes Single; punctate CM; upper pole 25 No   Yes Single; punctate Papillary; mid pole 26  No   27 No   No   28 No   No   CM:  corticomedullary  
1  
Table 3  Nephrocalcinosis Extent  Total  0 1 2 3 Mean Hydroxyapatite 4 0 3 7 1.98 14 Brushite 8 4 0 7 1.32 19 ICSF 28 6 0 0 0.18 34 
 
Table 4:  Metabolic data on patients who did or did not have nephrocalcinosis 
Nephrocalcinosis absent 40 
Missing metabolic studies 7 
 
Nephrocalcinosis present 27 
Missing metabolic studies 5 
 Nephrocalcinosis 
Absent(33) 
Nephrocalcinosis 
Present (22) 
P-
Value 
Urine volume (L/day) 1.96 ± 0.77 1.92 ± 0.65 0.82 
Urine pH 6.09 ± 0.40 6.22 ± 0.27 0.21 
Urine calcium (mg/day) 223.68 ± 100.67 287.39 ± 112.49 0.03 
Urine citrate (mg/day) 512.86 ± 277.07 435.02 ± 296.63 0.33 
Urine sulfate (mg/day) 44.49 ± 16.34 39.88 ± 17.81 0.33 
Urine ammonia (mmol/day) 35.71 ± 16.45 26.55 ± 8.85 0.03 
Urine oxalate (mg/day) 42.98 ± 17.10 36.09 ± 13.56 0.12 
Supersaturation calcium oxalate 7.923 ± 3.55 7.95 ± 2.90 0.97 
Supersaturation calcium phosphate 1.26 ± 0.734 1.73 ± 0.61 0.02 
Serum creatinine (mg/dL) 1.04 ± 0.212 0.99 ± 0.27 0.44 
Serum bicarbonate (mmol/L) 27.13 ± 2.09 26.34 ± 2.12 0.15 
Serum calcium (mg/dL) 9.22 ± 0.61 9.51 ± 0.62 0.07 
Figure 1. 
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